Local lung cancer drug approved
Print Edition
Hansoh Pharmaceutical Group said it has received market approval for the first domestic therapy for patients with non-small cell lung cancer with certain types of gene mutation.
“This marks a milestone for domestic targeted therapy for lung cancer which also fits with China’s health care blueprint to encourage local innovation,” said Lu Shun, who led the registrational study and is a professor at the Shanghai Chest Hospital affiliated with Jiao Tong University.
The almonertinib mesilate tablet from Jiangsu-based Hansoh Pharma is a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor for patients who are T790M mutation-positive.
It is the first of its kind which is locally developed to be approved by the National Medical Products Administration.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
